Observational studyThorax2022
Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data.
Observational study in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Guideline
- Sleep Apnea: The Slept-Upon Cardiovascular Risk Factor.Biomedicines · 2025Review
- Highlights of the Sleep and Breathing Conference 2025.Breathe (Sheffield, England) · 2025Article
- Impact of Hypopnoea Classifications on the Assessment of Sleep Disordered Breathing in Heart Failure.Cardiac failure review · 2025Review
- Positive Airway Pressure Therapies for Heart Failure: What Do the Trials Tell Us?Cardiac failure review · 2025Review
- Treating central sleep apnoea in heart failure: progressing one step at a time.European respiratory review : an official journal of the European Respiratory Society · 2024Article
- Sleep Apnea and Heart Failure-Current State-of-The-Art.International journal of molecular sciences · 2024Review
- Association of Sex With Cardiovascular Outcomes in Heart Failure Patients With Obstructive or Central Sleep Apnea.Journal of the American Heart Association · 2024Observational
- Central sleep apnoea: not just one phenotype.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- A call for precision medicine: Facing the challenge of sleep-disordered breathing in heart failure.Sleep medicine · 2023Article
- Insights into the Interaction of Heart Failure with Preserved Ejection Fraction and Sleep-Disordered Breathing.Biomedicines · 2023Review
- Sleep and Breathing Conference highlights 2023: a summary by ERS Assembly 4.Breathe (Sheffield, England) · 2023Article
- Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV): protocol and cohort profile.ERJ open research · 2023Article
- ERS International Congress 2022: highlights from the Sleep Disordered Breathing Assembly.ERJ open research · 2023Article
- Central Sleep Apnea with Heart Failure: Two Bad Bedfellows.Annals of the American Thoracic Society · 2023Article
- Identifying novel subgroups in heart failure patients with unsupervised machine learning: A scoping review.Frontiers in cardiovascular medicine · 2022Article
- Personalized management of sleep apnea in patients with atrial fibrillation: An interdisciplinary and translational challenge.International journal of cardiology. Heart & vasculature · 2021Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAdaptive servo ventilation (ASV) is contraindicated in patients with systolic heart failure (HF) who have a left ventricular ejection fraction (LVEF) below 45% and predominant central sleep apnoea (CSA). However, the effects of ASV in other HF subgroups have not been clearly defined.
objectiveThe European, multicentre, prospective, observational cohort trial, FACE, evaluated the effects of ASV therapy on morbidity and mortality in patients with HF with sleep-disordered breathing (SDB); 3-month outcomes in patient subgroups defined using latent class analysis (LCA) are presented.
methodsConsecutive patients with HF with predominant CSA (±obstructive sleep apnoea) indicated for ASV were included from 2009 to 2018; the non-ASV group included patients who refused/were noncompliant with ASV. The primary endpoint was time to composite first event (all-cause death, lifesaving cardiovascular intervention or unplanned hospitalisation for worsening of chronic HF). MEASUREMENTS AND MAIN
resultsBaseline assessments were performed in 503 patients, and 482 underwent 3-month follow-up. LCA identified six discrete patient clusters characterised by variations in LVEF, SDB type, age, comorbidities and ASV acceptance. The 3- month rate of primary outcome events was significantly higher in cluster 1 patients (predominantly men, low LVEF, severe HF, CSA; 13.9% vs 1.5%-5% in other clusters, p<0.01).
conclusionFor the first time, our data identified homogeneous patient clusters representing clinically relevant subgroups relating to SDB management in patients with HF with different ASV usage, each with a different prognosis. This may improve patient phenotyping in clinical practice and allow individualisation of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.